Introduction {#s1}
============

Over the past two decades, rates of opioid use have risen sharply around the world. Between 2001--03 and 2011--13, global opioid use doubled to more than 7.3 billion daily doses per year ([@B1]). The effects of this worrying trend have been most pronounced in the United States, where opioid misuse has become a national health concern ([@B1], [@B2]). Similar trends have emerged in Canada ([@B3]), parts of Central and Western Europe ([@B1]), and Australia ([@B4], [@B5]). Even in Norway and Sweden, where the overall prevalence of prescription opioid use has been comparatively stable over the last decade, there has been an increase in both the availability of the strong opioid oxycodone and oxycodone related deaths ([@B6], [@B7]).

The human and economic costs of opioid misuse are substantial. With more than 43,000 Americans dying from opioid overdoses in 2017 alone, opioids now kill more people than motor vehicle accidents in the US ([@B8]). Patients who are prescribed long-acting opioids face an increased risk of all-cause mortality relative to those prescribed other common pain medications ([@B9]), and upwards of 40% of suicide and overdose deaths in the US have a documented link to opioids ([@B10]). The total economic burden of opioids in the US alone was recently estimated to be \$504 billion per year ([@B11]). This headline figure included \$431.7 billion in costs associated with fatal opioid-involved overdoses, and \$72.3 billion in costs associated with non-fatal abuse and dependence due to increased healthcare, substance abuse treatment, and criminal justice spending, as well as reductions in productive employment ([@B11], [@B12]).

A growing amount of attention is rightly being paid to the widespread practice of prescribing opioids for postsurgical analgesia. In the US, surgeons wrote 28.3 million opioid prescriptions in 2012, which accounted for 9.8% of all opioid prescriptions written that year ([@B13]). In Australia, surgeons are responsible for 6.6% of patients being initiated onto opioid therapy each year ([@B4]). While opioids may be necessary to provide patients with adequate relief from acute pain after major surgery, their role at and beyond discharge calls for greater scrutiny. To make informed changes to the practice of postsurgical opioid prescribing, it is vital that we first understand the need for these changes, particularly in the setting of the risks associated with preoperative opioid use among surgical patients, the rate of persistent postsurgical opioid use, and risk factors associated with persistent use (see [Box 1](#Box1){ref-type="boxed-text"}). We must also be aware of how often excess opioids remain unused after surgery, and of what guidelines are currently available for postsurgical prescribing. This narrative review aims to provide an overview of the growing literature on these topics. Guided by the current evidence, we call for actions to be taken to address important research gaps and alleviate the harms associated with opioid use following surgery.

###### Defining the problems.

**Opioid misuse:** Opioid use that diverges from the prescribed pattern of use ([@B14]). This broader concept will include instances of opioid abuse and dependence.

**Opioid abuse:** Intentional opioid misuse that is for a non-medical purpose. This includes misuse that aims to elicit feelings of euphoria or alter one\'s state of consciousness ([@B14]).

**Opioid dependence:** A cluster of symptoms that may develop following repeated opioid use. Typical symptoms include difficulty controlling use, cravings, increased tolerance, physical withdrawal, and persistent use despite harmful consequences ([@B15]).

**Persistent postoperative use:** Opioid use that continues beyond the point at which acute postsurgical pain is expected to have resolved. While exact definitions vary, a recent consensus statement defines persistent use among opioid-naïve patients as the use of opioids for 60 days between postoperative days 90--365 ([@B16]).

**Excess opioid prescribing:** Prescribing a quantity of opioids that is more than the quantity that is ultimately consumed by the patient. Importantly, it is possible to inappropriately prescribe opioids (or prescribe a greater dosage than is necessary) even when the patient consumes their entire prescribed dose. For the purposes of this paper, this concept refers to prescribing that results in excess unused opioids rather than the medically unnecessary or suboptimal prescribing of opioids.

Persistent Use of Opioids After Surgery {#s2}
=======================================

Against the backdrop of opioid crises around the world, it is concerning that many patients who are prescribed opioids to alleviate acute postoperative pain progress to longer-term use. Initiating this transition to persistent postoperative use is likely one of the primary ways in which surgeons have contributed to opioid-related harm in the community. This is made all the more worrying by the fact that recent guidelines have emphasized that there is no strong evidence to support the effectiveness of long-term opioid therapy---but extensive evidence that long-term use is associated with substantial risks ([@B17], [@B18]). These include increased risk of opioid abuse or dependence, fatal and non-fatal overdose, endocrinological harms, cardiovascular events, and road trauma ([@B17]).

Despite this, there does not appear to be a widely accepted definition of persistent postoperative opioid use ([@B16]). Some definitions that have appeared in the literature include: continued use for more than 90 days after discharge ([@B19]), filling 10 or more prescriptions in the year after surgery ([@B20]), and either 90 days of continuous use or 120 days of non-continuous use after surgery ([@B21]). In an effort to standardize the definition of persistent postoperative use, the American Society for Enhanced Recovery recently issued a consensus statement ([@B16]). In this statement, persistent postoperative opioid use was defined differently for opioid-naïve and non-naïve patients. In opioid-naïve patients, persistent use was defined as using opioids for at least 60 days in the 90--365 days postoperative period. In non-naïve patients, persistent postoperative use was defined as an increase in opioid use in the 90--365 days postoperative period when compared to their use in the 90 days before surgery. The uptake of some form of standard measure would undoubtedly make future research among different populations more readily comparable and better placed to inform changes to health policy or prescribing practices.

Two recent systematic reviews have reported rates of persistent opioid use following surgery ([@B16], [@B22]). Mohamadi et al. ([@B22]) reported an overall rate of prolonged use of 4.3% (95% CI 2.3--8.2%) among 1.72 million surgical and trauma patients examined in 14 large population-based studies. Kent et al. ([@B16]) reviewed 47 studies that evaluated patients who had undergone procedures from five surgical subgroups ([Table 1](#T1){ref-type="table"}). From the moderate quality studies assessed, incidence of persistent postoperative use ranged from 0.6 to 26% for opioid-naïve patients and from 35 to 77% for non-naïve patients ([@B16]). While these reviews highlight the considerable number of studies that have quantified rates of persistent use, it is worth noting that there has been little qualitative research that specifically examines patients\' experiences of persistent postoperative opioid use or clinicians\' perceptions of the need for opioids after discharge from surgery. Such in-depth research could provide richer insight into the factors that contribute to patients\' long-term reliance on opioids after surgery.

###### 

Incidence of persistent postoperative opioid use in moderate quality studies reviewed by Kent et al. ([@B16]).

  **Surgery**                     **Opioid naïve sample (%)**   **Opioid non-naïve sample (%)**   **Mixed sample (%)**
  ------------------------------- ----------------------------- --------------------------------- ----------------------
  Total hip or knee replacement   0.6--4                        35--68                            5.5--32
  Abdominopelvic                  0.12--6                       59--77                            0.36--14
  Spine                           26                            59                                18--59
  Mastectomy                      10--11                        --                                --
  Thoracic                        14                            --                                --

Both reviews indicated that a non-trivial proportion of surgical patients are at risk of becoming persistent opioid users. Importantly, these reviews also highlighted several patient-related risk factors for postoperative use, including opioid use prior to surgery, benzodiazepine use, pain catastrophizing, depression, smoking, and preoperative pain conditions ([@B16], [@B22]). In addition to this, while both major and minor surgeries place patients at risk of developing persistent opioid use, Mohamadi et al. ([@B22]) reported that more invasive procedures were associated with greater odds persistent postoperative use. Each of these risk factors can be understood as a potential target for interventions aimed at reducing rates of persistent postoperative use. To date, the possibility of reducing persistent postoperative use by addressing known risk factors in the preoperative period has been largely overlooked. Research that aims to fill this gap has the potential to substantially reduce rates of prolonged reliance on opioids after surgery.

Risks Associated With Opioid Use Prior to Surgery {#s3}
=================================================

The most prominent risk factor for persistent postoperative use reported in both systematic reviews mentioned above is the use of opioids before surgery. Rates of persistent postoperative use reported by Kent et al. ([@B16]) were more than 10 times higher in non-naïve hip and knee replacement, and abdominopelvic patients when compared to opioid naïve patients. Mohamadi et al. ([@B22]) reported that preoperative use was associated with roughly 11 times greater odds of long-term postoperative use (OR = 11.04 \[95% CI 9.39--12.97\]). Preoperative opioid use has also been linked to poorer outcomes across most major surgical specialties ([@B23]--[@B30]). These adverse outcomes have been widely documented using measures such as length of stay ([@B27], [@B30]), readmission rate ([@B23], [@B27], [@B28]), postoperative cost of care ([@B24], [@B25], [@B31]), and complication rate ([@B25]). Among orthopedic patient populations, who often have high rates of use prior to surgery ([@B32]), preoperative opioid abuse and dependence is associated with significant increases in morbidity and mortality after surgery ([@B33]). Among patients undergoing total joint replacement, preoperative opioid use is associated with less postoperative improvement in patient reported pain and function ([@B34]). Furthermore, recent studies have found that preoperative opioid users who undergo joint replacement are significantly more likely to suffer a periprosthetic joint infection ([@B35]) or require surgical revision ([@B26], [@B36]). The mechanisms through which preoperative opioid use contributes to complications such as joint infection and early revision are almost certainly multifactorial. However, higher rates of postoperative opioid consumption among preoperative users and the immunosuppressive nature of some opioids have been suggested as key contributory factors ([@B35], [@B36]). Given the many ways in which preoperative opioid use may negatively impact clinical outcomes, it is likely that paying careful attention to this driver could contribute to improving the safety and quality of surgical care.

In the most general terms, there are three ways in which preoperative opioid use may be altered prior to surgery. The first, and most wide ranging, is to target the inappropriate prescribing of opioids among all patient populations. Lowering the overall prevalence of opioid use among the population as a whole would potentially be the most viable long-term strategy for reducing the rate of opioid use among patients presenting for surgery. Furthermore, there are particular surgical populations in which the reduction of inappropriate opioid prescribing is likely to drastically reduce the risks associated with preoperative opioid use. For instance, the rate of preoperative opioid use in total knee replacement patients has been reported at roughly 55% ([@B37]). This is despite guidelines strongly recommending against the use of opioids in light of strong evidence that opioids offer limited or no relevant benefit in the treatment of osteoarthritis ([@B38]). In fact, several randomized controlled trials have shown opioids to be no more effective in treating osteoarthritis-related pain than non-opioid analgesics such as acetaminophen or non-steroidal anti-inflammatories ([@B39], [@B40]). This suggests that increased uptake of evidence-based non-surgical treatment of knee and hip osteoarthritis could potentially eliminate preoperative opioid use among this specific and sizable population ([@B38]). Although such a shift may not impact all surgical populations to the same extent, it is imperative that measures be taken to limit inappropriate opioid prescribing whenever possible.

The second way that surgeons may attempt to reduce rates of preoperative opioid use is through timing elective surgeries prior to opioid initiation. In many instances this strategy will be infeasible. However, earlier progression to surgery may be possible for patients with degenerative conditions such as end-stage osteoarthritis where opioids may be inappropriately prescribed in an effort to delay or avoid inevitable surgery, despite strong recommendations against their use ([@B38], [@B41]). Such a pragmatic strategy concedes that inappropriate prescribing is not something that can be controlled entirely by optimal surgical care, and views delayed surgery as increasing the likelihood that patients will be prescribed opioids by another provider. A small amount of health economic research has shown that avoiding opioids through earlier surgery is a potentially cost-effective means of treating knee osteoarthritis ([@B42]) and the findings of this research stands to be tested in a variety of settings with this and other procedures. To date, there have been no studies that assess the feasibility or efficacy of such an approach among any surgical populations, targeting this as an important area for future research.

The third broad way that preoperative opioid use may be altered is through tapering or weaning patients from these medications prior to surgery ([@B43]). Unlike the first two strategies, this approach aims to respond to patients who have already been exposed to opioids, rather than preventing preoperative opioid initiation. Once again, there is little evidence about the feasibility or effectiveness of preoperative opioid weaning. In the only published study investigating links between preoperative weaning and surgical outcomes, patients who successfully weaned their dose by at least 50% before total joint replacement achieved improved clinical outcomes compared to patients who did not taper their use ([@B44]). Importantly, this study did not assess the impact of preoperative weaning on postoperative opioid use. Furthermore, the retrospective design of this study means it is possible that the observed differences are explained by variances in patient characteristics (e.g., tendency to comply with care) among those patients who successfully tapered their use compared with those who did not. Preoperative weaning interventions may also be infeasible because available evidence has not yet clarified how to best support patients to taper their opioid use ([@B45]). What\'s more, opioid tapering is not necessarily a risk-free endeavor, as there are concerns about it resulting in patients being at an increased risk of suicidal thoughts and behaviors ([@B46]), or transitioning to heroin use ([@B10], [@B47]). There is clearly a need for further research into the safety, efficacy, and feasibility of preoperative opioid tapering, given that such an intervention may both reduce rates of persistent opioid use and improve surgical outcomes more generally.

What Do We Know About Post-Operative Prescribing? {#s4}
=================================================

Variations in Postoperative Opioid Prescribing
----------------------------------------------

Opioids are one of the medicines most commonly prescribed by surgeons. In 2012, more than a third of prescriptions written by American surgeons were for opioids ([@B13]). Despite such a large portion of surgical prescriptions being for this one class of drug, there is little uniformity in how they are prescribed ([@B48]--[@B50]). Variability in prescribing practices has been documented in many different domains. In a recent study of pediatric umbilical hernia patients, rates of opioid prescribing varied significantly between census regions, with a rate of 42% in the Northeastern and 59% in the Southern United States ([@B50]). It is important to note that such disparities do not only exist on a regional level. In a study of 642 patients undergoing five different common surgical procedures at a single academic medical center, there was wide variation documented between different operations ([@B49]). There was also wide variation in prescriptions for patients undergoing the same procedure even when the procedure was conducted by the same provider ([@B49]). There is little direct research examining whether similar variation exists in surgical prescribing practices outside of the United States. However, given that significant regional variations in general opioid prescribing has been documented in several other countries ([@B51], [@B52]), it is reasonable to also expect similar variability in postsurgical prescribing.

In light of significant variations in the prevalence of prescription opioid use between countries ([@B1]), it is likely that surgical prescribing practices differ substantially between countries. Despite this, there has been a very limited amount of research that directly compares surgical prescribing patterns between countries, and until recently sample sizes in these studies have been small. In one study comparing opioid prescribing practices after operative treatment of hip and ankle fractures in 190 American and 116 Dutch patients, 82% of American patients and 6% of Dutch patients with ankle fractures were prescribed post-discharge opioids ([@B53]). Among hip fracture patients, 77% of the American and none of the Dutch patients were prescribed opioids after discharge. Another study, which compared opioid prescriptions for 820 patients undergoing head and neck surgeries in the US and Hong Kong, found that almost none of the patients in Hong Kong were prescribed opioids pre- or post-operatively ([@B54]). Recently, Ladha et al. ([@B55]) published the first large-scale cohort study comparing postoperative opioid prescribing between countries. By comparing opioid prescriptions following four minor surgical procedures in the US (129,379 patients), Canada (84,653 patients), and Sweden (9,802 patients), this study found opioid prescriptions in the US and Canada were filled at a 7-times greater rate than in Sweden. These findings highlight this as an important domain for future research. Such research could go beyond evaluating differences in prescribing after surgical procedures, to explore differences in patient satisfaction with pain control, surgical outcomes, and clinicians\' attitudes toward postoperative opioid prescribing. Observing variations in opioid prescribing both regionally and internationally is a vital preliminary means of assessing the feasibility of offering high quality surgical care while minimizing the pervasiveness of post-discharge opioid analgesia.

Unused Opioids After Surgery
----------------------------

Several studies have documented the over-supply of opioids after surgery. A systematic review that identified six studies reported that between 42 and 71% of prescribed opioid pills went unused ([@B56]). Another review, which identified 11 patient survey studies, found that between 40 and 94% of prescribed pills went unused, with one outlier reporting roughly 10% unused ([@B57]). Recently, Sabatino et al. ([@B58]) reported on a telephone survey of 198 patients who had undergone a total hip replacement and 146 had undergone a total knee replacement. Approximately 29% of prescribed pills were unused by hip replacement patients and 18% were unused by knee replacement patients. While these findings fall outside the ranges reported by the earlier reviews, this deviation was likely influenced by the fact that none of the studies included in the earlier reviews examined excess prescribing following total hip and knee replacement. To determine how the type of procedure impacts rates of excess opioid prescribing, and to properly inform surgeons\' prescribing practices, further research in this domain is clearly warranted. To this end, Thiels et al. ([@B59]) recently published a study evaluating rates of excess prescribing following 25 elective procedures, which found that overall 61% of prescribed opioids went unused. Despite the importance of this work, our understanding of excess prescribing following many procedures is still limited by relatively small samples. For instance, our current understanding of the rate of excess prescribing following hip replacement is drawn from two studies reporting on 348 total patients treated in four American hosptials. The narrow scope of this evidence, along with the fact that none of the research cited here has evaluated patient populations outside of North America, highlights an opportunity for novel research into the oversupply of opioids after surgery in other regions.

Reducing excess prescribing is likely to help combat opioid-related harm in at least two ways. First, reducing the size of postoperative opioid prescriptions has been associated with a reduction in the amount of opioids consumed by patients ([@B60]). Although the precise mechanism for this reduction in opioid consumption is not known, it is possible that it is a result of patients anchoring and adjusting their expectations to the smaller total prescription size ([@B60]). Second, minimizing excess prescribing may reduce the amount of opioids that are diverted to non-medical use. The reviews mentioned above reported that between 4 and 59% of patients planned proper disposal of their excess opioids ([@B56], [@B57]), which leaves a substanital portion of excess opioids available for diversion. Diversion resulting from large opioid prescriptions can have severe consequences. A recent study by Khan and colleagues reported that family members of patients who have been prescribed opioids face between 2.7 (OR, 2.71 95% CI, 2.42--3.03) and 15.1 (OR, 15.08 95% CI, 8.66--26.27) times greater odds of overdosing, with stronger prescriptions being associated with greater odds of overdose ([@B61]). Combatting both excess prescribing and poor disposal practices is likely the best way to reduce surgeons\' contributions to the harms associated with opioid diversion.

Summing Up: A Call for Further Research and Action {#s5}
==================================================

The available evidence calls for action in two domains (see [Box 2](#Box2){ref-type="boxed-text"}).

###### Evidence gaps.

**Targeting risk factors prior to surgery** 

-   Is targeting known risk factors prior to surgery a viable or effective means of reducing the rate of persistent use following surgery?

-   Can opioid-sparing multimodal analgesia after discharge reduce the prevalence of persistent postoperative opioid use or the risk of opioid-related harms following surgery?

-   Can risks associated with preoperative opioid use be reduced through preoperative opioid tapering?

-   Is earlier progression to elective surgery a viable and effective means of reducing patient\'s risk of being exposed to opioids prior to surgery?

-   What are the patterns and sources of preoperative opioid use?

-   Precisely what are the risks associated with preoperative opioid use?

**Optimizing postoperative opioid prescribing practices** 

-   What postoperative interventions effectively reduce rates of persistent postoperative opioid use?

-   Do available guidelines for postoperative opioid prescribing reduce the prevalence of opioid-related harms following surgery? Do these guidelines reduce rates of persistent postoperative opioid use?

-   Do rates of postoperative opioid prescribing differ between countries?

-   Do rates of persistent postoperative opioid consumption vary between countries?

-   To what extent do opioids prescribed after surgery remain unused by patients outside of North America?

First, surgical care must become more responsive to risk factors associated with persistent postoperative opioid use. The literature has identified several important risk factors; however, to date, there have been no rigorous evaluations of interventions that specifically aim to target these risk factors. Combatting the most significant known risk factor for persistent postoperative use---opioid use prior to surgery---will require action on many fronts. First and foremost, it is essential that inappropriate opioid prescribing is minimized among surgical populations that are at high risk of being prescribed opioids prior to surgery. Despite limited evidence of any benefit and strong evidence of dose-dependent risks ([@B62]), vast numbers of patients are still being prescribed opioids for chronic non-cancer pain such as that caused by end-stage osteoarthritis. This poses the question: how do we ensure that what we already know is put into practice? The design and implementation of interventions in this domain ought to be informed by multidisciplinary and qualitative research exploring why clinicians across all major specialties prescribe opioids inappropriately, and why patients perceive the need for opioids prior to surgery. Evaluating the potential efficacy of interventions that aim to reduce inappropriate opioid prescribing at such a general level will require high quality retrospective data, as sufficiently powered clinical trials are likely to be infeasible. In addition to this, surgeons may wish to be mindful of the timing of elective surgeries to minimize the risk that patients will be initiated onto opioids by another provider. This may include such practices as closely monitoring and managing surgical waiting lists to ensure timely surgery. To date, no studies have assessed the impact of reducing waiting times to surgery and its impact on post-operative opioid use, or how this strategy of reducing waiting times may reduce preoperative opioid intake. Finally, as many patients presenting for surgery have already been initiated onto opioids, there is a pressing need for rigorous clinical trials to evaluate the safety, efficacy, and feasibility of preoperative opioid tapering, given that such an intervention may reduce rates of persistent postoperative opioid use while also improving surgical outcomes more generally.

Second, post-discharge prescribing practices need to be optimized to limit patients\' risk of persistent postoperative use. The prevalence of excess prescribing and wide variations in prescribing practices indicate that there is substantial scope to improve current post-discharge prescribing practice ([@B48], [@B50]). One approach to optimizing prescribing practices is ensuring that patients are discharged home with carefully constructed multimodal analgesia regimens (e.g., NSAID, Acetaminophen, Gabapentin), to minimize reliance upon opioids following discharge. Multimodal analgesia has consistently been shown to reduce in-hospital opioid consumption ([@B63]). However, to date, there is a little research examining multimodal analgesia\'s impact on persistent postoperative opioid use or its long-term efficacy following surgery ([@B64]). In addition to this, the widely publicized successes of the CDC\'s *Guideline for Prescribing Opioids for Chronic Pain* indicate that guidelines can have a significant positive impact on opioid prescribing practices ([@B65]). A limited number of guidelines have been proposed for postsurgical opioid prescribing ([@B59], [@B66]--[@B68]). However, unlike the CDC guideline, these recommendations have drawn on a relatively narrow band of evidence. In particular, they have largely drawn on evidence about the actual consumption of opioids after surgery among American cohorts to determine how to manage a significant majority of patients\' pain while limiting the number of unused opioids available for diversion ([@B59], [@B67], [@B68]). That is to say, these guidelines have been constructed with the primary aim of reducing the overall amount of opioids prescribed and consumed following surgery. While this is a worthwhile aim, it is unclear whether this should be the only---or the primary---aim of discharge prescribing guidelines. The total number or dosage of opioids prescribed to patients following surgery is, after all, an indirect proxy for patients\' risk of opioid-related harm. Thus, future research evaluating the efficacy of interventions to reduce postoperative prescribing ought to directly measure rates of opioid-related harm alongside the total amount of opioids being prescribed. In addition to this, to ensure that prescribing practices do not over-correct, it is vital that such research is mindful of patients\' pain and quality of life.

In addition, it is important to note that early guidelines have largely drawn conclusions about optimal prescribing practices by monitoring opioid consumption in the US---which is the epicenter of the global opioid crisis. While such an approach has shown the potential to reduce rates of excess prescribing, it is unclear that it is the most appropriate way to formulate recommendations for postoperative prescribing. More ambitious guidelines could anchor future recommendations to prescription practices or levels of consumption in nations that offer high quality surgical care while prescribing markedly fewer opioids after surgery. Countries like Sweden where prescriptions are filled at a seven-times lower rate than in North America, offer a vital source of evidence about how significantly opioid prescribing practices could be altered in countries like the US without compromising the quality of surgical care ([@B55]). Collecting data to inform the development of such prescribing recommendations is likely to require long-term international collaborations at a scale that has yet to emerge among researchers in this field. Such collaborations are necessary not only to inform the next wave of postoperative prescribing guidelines, but also to rigorously examine if implementing similarly restrictive prescribing practice is feasible across nations. To this end, the Consortium Against the overuse of Opioids in Surgery (CAOS) has been formed as a multinational (American, European, Oceania) initiative to address the research issues raised in this review.
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